AMPK has been highlighted as a target for obesity prevention and therapy because of its role in suppressing fatty acid synthesis and inducing β-oxidation by inhibiting ACC and SREBP1 [43], as well as in the development of mitochondrial biogenesis and adipocyte browning by activating UCP1 [9]. The gene discussed is SREBF1; the disease is obesity due to melanocortin 4 receptor deficiency.